Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials

Qingyuan HuangDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

Hua ZhangDepartment of Surgery and Cancer, Imperial College London, London, UK

Josephine HaiDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA

Mark A. SocinskiThoracic Oncology Program, Florida Hospital Cancer Institute, Orlando, Florida, USA

Eric LimImperial College London and The Academic Division of Thoracic Surgery, Royal Brompton Hospital, London, UK

Haiquan ChenDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

Justin StebbingDepartment of Surgery and Cancer, Imperial College London, London, UKCorrespondence[email protected]

Your download is now in progress and you may close this window